
Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
VITALIZE Venture Capital is a venture capital firm founded in 2018 and headquartered in the United States. The firm focuses on seed-stage investments, particularly in the WorkTech sector, which encompasses businesses that enhance workplace productivity and efficiency through technology. Initially, VITALIZE launched with a $16 million fund and has successfully raised a $23 million Fund II, which is currently being deployed to support promising startups.
The firm operates with a clear mission to invest in B2B and B2B2C software companies that are incorporated in the U.S. VITALIZE has established itself as a key player in the seed-stage investment landscape, emphasizing a people-first, data-driven approach to identify and support companies that address significant market pain points.
VITALIZE Venture Capital invests exclusively in seed-stage B2B and B2B2C software companies that have completed product development and achieved early customer revenues. The firm specifically targets companies with an annual recurring revenue (ARR) of $500,000 or more. Their investment strategy excludes hardware and direct-to-consumer (DTC) businesses, allowing them to concentrate on software solutions that can scale effectively.
Initial check sizes range from $250,000 to $750,000, and VITALIZE prefers to invest in companies that are less than three years old, with a post-money valuation of less than $20 million. This focused approach enables VITALIZE to support startups that are addressing significant challenges in large and growing markets, aligning with their emphasis on a data-driven investment philosophy.
Gale Wilkinson - Founder and Managing Partner. Gale has extensive experience in venture capital and entrepreneurship, having previously worked with various startups and investment firms. She is known for her expertise in identifying promising technology companies and has a strong background in supporting early-stage ventures.
Waela Fellnert - Marketing & Communications Manager. Waela brings a wealth of knowledge in marketing strategies and communications, helping to enhance VITALIZE's visibility and engagement with the startup community.
To pitch VITALIZE, founders should visit their website at vitalize.vc. It is important to include a comprehensive pitch deck that outlines the business model, market opportunity, and traction. VITALIZE does not specify a formal application process, but a well-structured pitch is essential for consideration.
What are VITALIZE's investment criteria?
VITALIZE focuses on seed-stage B2B and B2B2C software companies incorporated in the U.S. They look for companies that have completed product development and have early customer revenues, specifically those with an ARR of $500,000 or more.
How can I pitch to VITALIZE?
Founders can submit their pitches through the VITALIZE website at vitalize.vc. It is recommended to include detailed information about the product, market opportunity, and traction in the pitch deck.
What makes VITALIZE different from other investors?
VITALIZE emphasizes a people-first, data-driven approach, focusing on startups that address significant market pain points. Their specific focus on the WorkTech sector allows them to provide tailored support to portfolio companies.
What is the typical check size for investments?
VITALIZE typically writes initial checks ranging from $250,000 to $750,000 for their seed-stage investments.
What is the geographic focus of VITALIZE?
VITALIZE exclusively invests in companies that are incorporated in the United States.
What is the target post-money valuation for investments?
VITALIZE targets companies with a post-money valuation of less than $20 million.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.